Enanta Pharmaceuticals, Inc. (FRA:9EP)
Germany
· Delayed Price · Currency is EUR 11.90
-0.10 (-0.83%)
Last updated: Dec 4, 2025, 7:55 PM CET
Enanta Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2016 - 2020 |
| Cash & Equivalents | 32.3 | 37.23 | 85.39 | 43.99 | 57.21 | Upgrade
|
| Short-Term Investments | 156.57 | 210.95 | 284.52 | 205.24 | 186.8 | Upgrade
|
| Cash & Short-Term Investments | 188.86 | 248.19 | 369.91 | 249.23 | 244 | Upgrade
|
| Cash Growth | -23.90% | -32.91% | 48.42% | 2.14% | -36.89% | Upgrade
|
| Accounts Receivable | 6.88 | 6.65 | 8.61 | 20.32 | 23.58 | Upgrade
|
| Other Receivables | - | 32 | 31 | 28.72 | 37.26 | Upgrade
|
| Receivables | 6.88 | 38.65 | 39.62 | 49.04 | 60.83 | Upgrade
|
| Prepaid Expenses | 8.59 | 12.41 | 13.26 | 13.45 | 14.19 | Upgrade
|
| Restricted Cash | - | 0.61 | - | - | - | Upgrade
|
| Total Current Assets | 204.34 | 299.85 | 422.79 | 311.71 | 319.02 | Upgrade
|
| Property, Plant & Equipment | 72.94 | 73.35 | 34.71 | 29.75 | 10.65 | Upgrade
|
| Long-Term Investments | - | - | - | 29.29 | 108.42 | Upgrade
|
| Other Long-Term Assets | 3.45 | 3.45 | 4.77 | 4.66 | 0.7 | Upgrade
|
| Total Assets | 280.73 | 376.65 | 462.28 | 375.41 | 438.79 | Upgrade
|
| Accounts Payable | 1.95 | 8 | 4.1 | 6 | 9.54 | Upgrade
|
| Accrued Expenses | 12.75 | 13.55 | 18.34 | 20.94 | 22.43 | Upgrade
|
| Current Portion of Long-Term Debt | 30.71 | 34.46 | 35.08 | - | - | Upgrade
|
| Current Portion of Leases | 3.15 | 1.52 | 5.28 | 2.89 | 4.2 | Upgrade
|
| Total Current Liabilities | 48.56 | 57.54 | 62.79 | 29.83 | 36.17 | Upgrade
|
| Long-Term Debt | 112.44 | 136.13 | 160.85 | 1.42 | 1.51 | Upgrade
|
| Long-Term Leases | 54.76 | 53.94 | 21.24 | 22.37 | 1.13 | Upgrade
|
| Other Long-Term Liabilities | 0.26 | 0.23 | 0.66 | 0.45 | 0.56 | Upgrade
|
| Total Liabilities | 216.02 | 247.84 | 245.54 | 54.08 | 39.36 | Upgrade
|
| Common Stock | 0.21 | 0.21 | 0.21 | 0.21 | 0.2 | Upgrade
|
| Additional Paid-In Capital | 469.77 | 451.34 | 424.69 | 398.03 | 351.03 | Upgrade
|
| Retained Earnings | -404.93 | -323.04 | -207 | -73.18 | 48.58 | Upgrade
|
| Comprehensive Income & Other | -0.34 | 0.3 | -1.17 | -3.72 | -0.38 | Upgrade
|
| Shareholders' Equity | 64.72 | 128.81 | 216.74 | 321.33 | 399.43 | Upgrade
|
| Total Liabilities & Equity | 280.73 | 376.65 | 462.28 | 375.41 | 438.79 | Upgrade
|
| Total Debt | 201.06 | 226.06 | 222.44 | 26.69 | 6.84 | Upgrade
|
| Net Cash (Debt) | -12.19 | 22.13 | 147.47 | 251.83 | 345.58 | Upgrade
|
| Net Cash Growth | - | -85.00% | -41.44% | -27.13% | -15.65% | Upgrade
|
| Net Cash Per Share | -0.57 | 1.05 | 7.03 | 12.22 | 17.13 | Upgrade
|
| Filing Date Shares Outstanding | 28.86 | 21.19 | 21.06 | 20.8 | 20.32 | Upgrade
|
| Total Common Shares Outstanding | 21.39 | 21.19 | 21.06 | 20.79 | 20.24 | Upgrade
|
| Working Capital | 155.78 | 242.32 | 360 | 281.89 | 282.85 | Upgrade
|
| Book Value Per Share | 3.03 | 6.08 | 10.29 | 15.46 | 19.74 | Upgrade
|
| Tangible Book Value | 64.72 | 128.81 | 216.74 | 321.33 | 399.43 | Upgrade
|
| Tangible Book Value Per Share | 3.03 | 6.08 | 10.29 | 15.46 | 19.74 | Upgrade
|
| Machinery | 20.39 | 19.92 | 19.14 | 16.79 | 16.32 | Upgrade
|
| Construction In Progress | - | 22.75 | 1.27 | 2.56 | 0.02 | Upgrade
|
| Leasehold Improvements | 38.2 | 13.98 | 13.8 | 7.28 | 7.14 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.